Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
Case Number:
Case Type:
IPR
Status:
Final Written Decision
Petitioner:
Eli Lilly and Company
Patent Owner:
Teva Pharmaceuticals International GmbH
Patent Number:
Tech Center:
1600
-
November 08, 2022
Eli Lilly Flips Teva 'Free Ride' Claim As Migraine Trial Wraps
Three weeks after Teva Pharmaceuticals opened a patent infringement suit by accusing Eli Lilly and Co. of free riding on intellectual property undergirding its migraine drug, Lilly told the jury Tuesday its rival is the real culprit after it "hopped into a de-risked market."
-
October 19, 2022
Teva Slams Eli Lilly's 'Free Ride' On Migraine IP As Trial Opens
Teva Pharmaceuticals kicked off its migraine drug patent infringement trial against Eli Lilly and Co. on Wednesday, telling a Boston federal jury that the rival shouldn't be allowed to "free ride" on its hard-won research to rake in sales for a similar treatment.
-
April 01, 2020
PTAB Upholds 3 Teva Migraine Patents Challenged By Eli Lilly
The Patent Trial and Appeal Board upheld all claims in three Teva Pharmaceutical patents covering its migraine biologic Ajovy that were challenged by Eli Lilly, giving a boost to Teva's underlying infringement suit against its rival over a competing drug.